论文部分内容阅读
为探讨妇科良、恶性肿瘤患者CD3AK细胞体外对肿瘤细胞的杀伤活性，将5例妇科良性肿瘤，12例妇科恶性肿瘤患者的外周血单个核细胞制备成CD3AK细胞，用MTT法测定CD3AK细胞对卵巢癌细胞系（3AO）的杀伤活性，同时观察不同效靶比的杀瘤情况，每周测定1次，共4周。结果：①良性肿瘤组CD3AK细胞对3AO的杀伤活性随着效靶比的增大而增强，在培养第1、4周，效靶比为20：1和40：1的杀瘤活性明显高于10：1；动态观察其杀瘤活性，培养第2周最低，第3、4周则较强；②恶性肿瘤组CD3AK细胞杀瘤活性当效靶比为10：1时低于20：1和40：1；动态观察其杀瘤活性，培养第2、3周高于第1、4周；③良、恶性肿瘤相比，CD3AK细胞杀瘤活性于培养第2周恶性肿瘤组显著高于良性肿瘤组（10：1，20：1）（P＜0．05），培养第4周（20：1）良性肿瘤组又显著高于恶性肿瘤组（P＜0．05）。结果提示：良、恶性妇科肿瘤患者CD3AK细胞对肿瘤的杀伤活性并不相同，临床上应针对良、恶性肿瘤患者CD3AK细胞的各自特点，选择适宜的治疗时间。
To investigate the killing activity of CD3AK cells on tumor cells in benign and malignant gynecological patients in vitro, five peripheral blood mononuclear cells of gynecological benign tumors and 12 patients with gynecologic malignant tumors were prepared into CD3AK cells. The expression of CD3AK cells in ovary Cancer cell lines (3AO) killing activity, while observing different effect target kill ratio, killing once a week, a total of 4 weeks. Results: ① The killing activity of CD3AK cells to 3AO in benign tumor group increased with the increase of effective target ratio. The cytotoxicity of target cells at 20: 1 and 40: 1 was significantly higher than that at the first and the fourth week The killing activity of CD3AK cells in malignant tumor group was lower than 20: 1 when the effective target ratio was 10: 1 and 40: 1. The killing activity of CD3AK cells was higher than that of the 1st and 2nd week of the 2nd and 3rd week after culture. ③The killing activity of CD3AK cells in benign and malignant tumors was significantly higher than that in benign and malignant tumors Tumor group (10: 1, 20: 1) (P <0.05). In the fourth week (20: 1) benign tumor group was significantly higher than the malignant tumor group (P <0.05). The results suggest that the killing activity of CD3AK cells in benign and malignant gynecological tumors is not the same, and the appropriate treatment time should be selected according to the characteristics of CD3AK cells in patients with benign and malignant tumors.